Jennifer A Woyach Selected Research

ibrutinib

1/2022	Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study.
1/2022	Depth of response and progression-free survival in chronic lymphocytic leukemia patients treated with ibrutinib.
1/2022	Differential regulation of CTLA4 expression through BTK-dependent and independent mechanisms in CLL.
12/2021	The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib.
11/2021	Rare t(X;14)(q28;q32) translocation reveals link between MTCP1 and chronic lymphocytic leukemia.
11/2021	Significance of chromosome 2p gain in ibrutinib-treated chronic lymphocytic leukemia patients.
11/2021	A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia.
10/2021	Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202.
1/2021	Natural history of noninfectious, ibrutinib-attributable adverse events in patients with chronic lymphocytic leukemia.
1/2021	Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jennifer A Woyach Research Topics

Disease

63	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 10/2022 - 04/2011
28	Neoplasms (Cancer) 01/2022 - 01/2009
5	Leukemia 11/2021 - 04/2011
5	Disease Progression 01/2019 - 01/2009
4	Lymphocytosis 01/2020 - 03/2014
4	Lymphoid Leukemia 12/2019 - 01/2017
4	Lymphoma (Lymphomas) 11/2019 - 08/2017
3	Chromosome Aberrations (Chromosome Abnormalities) 12/2021 - 03/2010
3	Hypertension (High Blood Pressure) 10/2021 - 11/2019
3	Hematologic Neoplasms (Hematological Malignancy) 01/2021 - 01/2018
3	Tumor Lysis Syndrome 10/2020 - 12/2014
3	B-Cell Lymphoma (Lymphoma, B Cell) 12/2019 - 10/2018
2	Atrial Fibrillation 10/2021 - 12/2019
2	Infections 10/2021 - 01/2020
2	Neutropenia 01/2020 - 12/2014
2	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2019 - 12/2016
2	Agammaglobulinemia (Hypogammaglobulinemia) 07/2015 - 05/2015
2	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 08/2012 - 01/2012
2	Thyroid Neoplasms (Thyroid Cancer) 09/2009 - 01/2009
2	medullary Thyroid cancer 09/2009 - 01/2009
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2022
1	Abnormal Karyotype 12/2020
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2020
1	B-Cell Leukemia (Leukemia, B Cell) 11/2019
1	Thrombosis (Thrombus) 11/2019
1	Opportunistic Infections (Opportunistic Infection) 10/2019
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2018
1	Tetraploidy 08/2017
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 03/2016
1	Prolymphocytic Leukemia 08/2015
1	Thrombocytopenia (Thrombopenia) 12/2014
1	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 12/2014
1	Febrile Neutropenia 12/2014
1	Communicable Diseases (Infectious Diseases) 10/2013
1	Parasitic Diseases (Parasitic Disease) 10/2013
1	Tonsillar Neoplasms 03/2010
1	follicular Thyroid cancer 09/2009
1	Anaplastic Thyroid Carcinoma 09/2009

Drug/Important Bio-Agent (IBA)

47	ibrutinibIBA 01/2022 - 10/2013
25	Agammaglobulinaemia Tyrosine KinaseIBA 01/2022 - 10/2013
9	acalabrutinibIBA 01/2022 - 06/2017
8	venetoclaxIBA 12/2021 - 08/2015
8	Proteins (Proteins, Gene)FDA Link 12/2020 - 05/2013
7	obinutuzumabIBA 01/2022 - 10/2018
4	idelalisibIBA 11/2019 - 01/2012
3	Rituximab (Mabthera)FDA Link 11/2021 - 04/2011
3	Phosphotransferases (Kinase)IBA 11/2019 - 01/2015
3	MicroRNAs (MicroRNA)IBA 01/2018 - 12/2016
2	selinexorIBA 01/2022 - 05/2015
2	Chlorambucil (Leukeran)FDA Link 01/2022 - 01/2020
2	Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA 11/2021 - 04/2011
2	Bendamustine Hydrochloride FDA Link 11/2021 - 12/2018
2	duvelisibIBA 11/2019 - 12/2014
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 07/2015 - 05/2015
2	Proteasome InhibitorsIBA 01/2015 - 05/2013
2	carfilzomibIBA 01/2015 - 05/2013
2	Imatinib Mesylate (Gleevec)FDA Link 08/2012 - 01/2012
1	AntibodiesIBA 10/2022
1	CTLA-4 AntigenIBA 01/2022
1	SNX-5422IBA 01/2021
1	pirtobrutinibIBA 01/2021
1	Exportin 1 ProteinIBA 01/2021
1	Pneumococcal Vaccines (Pneumococcal Polysaccharide Vaccine)IBA 12/2020
1	Lenalidomide (CC 5013)FDA Link 12/2020
1	Warfarin (Coumadin)FDA LinkGeneric 01/2020
1	Immunoglobulin Variable RegionIBA 01/2020
1	Vitamin K FDA Link 01/2020
1	Biological ProductsIBA 10/2019
1	Glucocorticoid Receptors (Glucocorticoid Receptor)IBA 01/2019
1	IGF-I-IGFBP-3 complex FDA Link 01/2019
1	Biomarkers (Surrogate Marker)IBA 01/2019
1	thiamine triphosphorate (TTP)IBA 01/2019
1	GlucocorticoidsIBA 01/2019
1	Monoclonal AntibodiesIBA 10/2018
1	Serine (L-Serine)FDA Link 01/2018
1	PLX51107IBA 01/2018
1	Cysteine (L-Cysteine)FDA Link 01/2018
1	Messenger RNA (mRNA)IBA 04/2017
1	Mitogen-Activated Protein KinasesIBA 04/2017
1	Chimeric Antigen ReceptorsIBA 03/2016
1	ofatumumab FDA Link 08/2015
1	Type C PhospholipasesIBA 07/2015
1	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2015
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 12/2014
1	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 12/2014
1	AntigensIBA 02/2014
1	Tyrosine Kinase InhibitorsIBA 08/2012
1	Phosphatidylinositol 3-Kinases (PI 3 Kinase)IBA 01/2012
1	fludarabineIBA 04/2011
1	Dacarbazine (DIC)FDA LinkGeneric 03/2010
1	Vorinostat FDA Link 01/2009
1	Therapeutic UsesIBA 01/2009
1	Histone Deacetylase InhibitorsIBA 01/2009

Therapy/Procedure

35	Therapeutics 10/2022 - 01/2009
3	Drug Therapy (Chemotherapy) 11/2020 - 01/2009
2	Immunotherapy 01/2022 - 08/2017
1	Aftercare (After-Treatment) 01/2019
1	Ligation 02/2014
1	Molecular Targeted Therapy 09/2009
1	Duration of Therapy 01/2009